ArticleSage open pediatrics
Improved Impact on Clinical Outcomes and Reduced Cost of Care Associated With Switching Hypoallergenic Amino Acid-Based Formulas.
Article in Sage open pediatrics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amino acid-based formulas (AAF) contain free amino acids as their protein source and are indicated for certain gastrointestinal and medical conditions. When switching formulas, monitoring tolerance helps assure adequate nutritional management. A cross-sectional retrospective study was conducted using U.S. insurance claims data from 402 children switched from one AAF (Formula1) to a different AAF (Formula2) between June 2021 and April 2023 during the nationwide formula shortage. Database was analyzed for age, sex, comorbidities, clinical symptoms, and healthcare encounters. Mean age was 5.3 ± 4.7 years (60% male). Significantly fewer children experienced abdominal distention, diarrhea, flatulence, nausea/vomiting, and allergy symptoms 1-, 3-, 6-months post-switch to Formula2 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.